Thia T J K, Tan H H, Chuah T H C, Chow W C, Lui H F
Department of Gastroenterology and Hepatology, Singapore General Hospital, Outram Road, Singapore 169608.
Singapore Med J. 2008 Mar;49(3):e86-9.
Imatinib mesylate (Gleevec) is widely-used in the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour. Up to four percent of patients treated with imatinib may develop hepatotoxicity, which usually resolves with discontinuation of the drug. We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with herpetic rash and acute liver failure. This case illustrates the diagnostic challenges in the management of such a patient, as well as the need for greater vigilance in the monitoring of liver function tests for patients treated with imatinib. A short review on imatinib-related hepatotoxicity is also presented.
甲磺酸伊马替尼（格列卫）广泛应用于慢性髓性白血病（CML）和胃肠道间质瘤的治疗。接受伊马替尼治疗的患者中，高达4%可能会出现肝毒性，通常在停药后可缓解。我们报告了一名45岁的中国男性CML患者，同时感染慢性乙型肝炎病毒，正在接受伊马替尼治疗，出现疱疹样皮疹和急性肝衰竭。该病例说明了此类患者管理中的诊断挑战，以及对接受伊马替尼治疗的患者进行肝功能测试监测时需要提高警惕。还对伊马替尼相关肝毒性进行了简要综述。
